PMID- 26041375
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20220318
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 50
IP  - 3
DP  - 2015 Dec
TI  - A gene-disease association study of IL18 in thyroid cancer: genotype and 
      haplotype analyses.
PG  - 698-707
LID - 10.1007/s12020-015-0623-9 [doi]
AB  - Thyroid cancer is the most common malignancy of the endocrine system, and genetic 
      factors have been shown to be associated with its risk. Interleukin-18 (IL-18) is 
      a pleiotropic pro-inflammatory cytokine that induces IFN-gamma production and is 
      involved in T helper type 1 development. To determine the role of IL-18 gene in 
      thyroid cancer susceptibility, we conducted a case-control study, and genotyped 
      five single nucleotide polymorphisms (SNPs) in IL-18 gene (-656 G/T (rs1946519), 
      -607 C/A (rs1946518), and -137 G/C (rs187238) in the promoter region and +113 T/G 
      (rs360718) and +127 C/T (rs360717) in 5'-untranslated region) in 105 patients 
      with thyroid cancer and 148 healthy controls from Iranian population. Polymerase 
      chain reaction-restriction fragment length polymorphism (PCR-RFLP) and 
      allele-specific primer-PCR were used for genotyping. The association of different 
      genotypes with thyroid cancer, tumor type, and the tumor stage was analyzed. 
      Comparing all of the patient population with the controls, TT genotype at 
      position -656 G/T was observed to be associated with a significantly increased 
      risk of thyroid cancer [31/105 (30.1 %) vs 19/148 (13.1 %), p = 0.002, OR 2.90, 
      CI 1.40-5.70]. No association with thyroid cancer was found at other positions 
      (-607 C/A, -137 G/C, +113 T/G, and +127 C/T). Excluding the patients with 
      medullary carcinoma, and including only the ones with thyroid cancer derived from 
      the follicular epithelium, nearly the same results were observed regarding the 
      genotypes at position -656 G/T. Furthermore, significantly decreased risk of 
      thyroid cancer derived from the follicular epithelium was observed upon 
      inheritance of the homozygote genotype (CC) at position +127 C/T (40/94 (42.5 %) 
      versus 84/148 (56.8 %) in patients and controls, respectively (OR 0.56, 95 % CI 
      for OR 0.32-0.98, p = 0.04). Haplotype analysis indicated that among 32 possible 
      haplotypes, TAGTT haplotype frequency was significantly higher in patients than 
      in controls [12/188 (6.4 %) vs 2/292 (0.7 %), p = 0.0008] and this difference 
      resisted Bonferroni correction (n = 19) and significant level set at 0.003. 
      Nearly the same results were observed after excluding the patients with medullary 
      carcinoma. No association was found between the SNPs and the stage of tumor. Our 
      results suggest the increased susceptibility to thyroid cancer in subjects with 
      TT genotype at position -656 G/T of the promoter of IL-18 gene, as well as TAGTT 
      haplotype emerged from five studied SNPs in IL-18 gene. The data also suggest 
      that the inheritance of +127 CC genotype may protect individuals from thyroid 
      cancer derived from follicular epithelium.
FAU - Abdolahi, Farzan
AU  - Abdolahi F
AD  - Cancer Immunology Group, Shiraz Institute for Cancer Research, School of 
      Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
AD  - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Dabbaghmanesh, Mohammad Hossein
AU  - Dabbaghmanesh MH
AD  - Endocrinology and Metabolism Research Center, Nemazee Hospital, Shiraz University 
      of Medical Sciences, Shiraz, Iran.
FAU - Haghshenas, Mohammad Reza
AU  - Haghshenas MR
AD  - Cancer Immunology Group, Shiraz Institute for Cancer Research, School of 
      Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Ghaderi, Abbas
AU  - Ghaderi A
AD  - Cancer Immunology Group, Shiraz Institute for Cancer Research, School of 
      Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Erfani, Nasrollah
AU  - Erfani N
AD  - Cancer Immunology Group, Shiraz Institute for Cancer Research, School of 
      Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 
      erfanin@sums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150604
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (IL18 protein, human)
RN  - 0 (Interleukin-18)
RN  - Thyroid cancer, medullary
SB  - IM
MH  - Adult
MH  - Carcinoma/*genetics
MH  - Carcinoma, Neuroendocrine/*genetics
MH  - Carcinoma, Papillary
MH  - Case-Control Studies
MH  - Female
MH  - Genotype
MH  - Haplotypes
MH  - Humans
MH  - Interleukin-18/*genetics
MH  - Male
MH  - Middle Aged
MH  - Thyroid Cancer, Papillary
MH  - Thyroid Neoplasms/*genetics
OTO - NOTNLM
OT  - Haplotype
OT  - IL-18
OT  - Polymorphism
OT  - Thyroid cancer
EDAT- 2015/06/05 06:00
MHDA- 2016/09/27 06:00
CRDT- 2015/06/05 06:00
PHST- 2014/12/24 00:00 [received]
PHST- 2015/04/29 00:00 [accepted]
PHST- 2015/06/05 06:00 [entrez]
PHST- 2015/06/05 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - 10.1007/s12020-015-0623-9 [pii]
AID - 10.1007/s12020-015-0623-9 [doi]
PST - ppublish
SO  - Endocrine. 2015 Dec;50(3):698-707. doi: 10.1007/s12020-015-0623-9. Epub 2015 Jun 
      4.